A new Ebola vaccine produced by the University of Oxford has entered clinical trials.
The vaccine is intended to combat the Ebola strains from Zaire and Sudan, which have combined to cause nearly all Ebola outbreaks and deaths globally.
The University of Oxford has begun phase one of its studies, which will involve putting the vaccine to the test in human volunteers.
Although there are Ebola vaccinations available for the Zaire variety, Oxford researchers believe that the new vaccine will reach a wider audience.
Teresa Lambe, the University of Oxford’s principal scientific investigator, said: “Infected nations continue to see sporadic Ebolavirus outbreaks, putting the lives of individuals, particularly frontline health professionals, in danger. To combat this deadly disease, we need additional vaccines.”
There are four different Ebola virus species that have been linked to human disease. Zaire is the most dangerous of the three, causing death in 70% to 90% of patients if left untreated.
The novel vaccine created by Oxford researchers is based on a weaker variant of the common cold virus that has been genetically engineered to prevent it from replicating in people.
The Oxford-AstraZeneca Covid-19 vaccine was developed using this strategy, and it was a success.
At the institution, 26 participants aged 18 to 55 will receive one dose of the ChAdOx1 biEBOV Ebola vaccine in phase one of the studies. The results will be available in the second quarter of 2022, after they have been evaluated for six months.